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Enhanced renal leukotriene production in murine lupus: Role of
lipoxygenase metabolites. To investigate the potential role of leuko-
trienes in murine lupus, we measured renal hemodynamics and renal
leukotriene production in MRL-lprllpr mice at 12 and 20 weeks of age.
Over this age range, these animals develop overt manifestations of
autoimmune disease with nephritis similar to human SLE. In the
current study, we demonstrated that glomerular filtration rate (GFR)
and PAH clearance (CPAH) deteriorated with age in MRL-lpr/lpr mice,
but not in MRL-+/+ controls. Impaired renal hemodynamic function in
MRL-lprllpr mice was associated with enhanced ionophore-stimulated
production of both leukotriene B4 (LTB4) and leukotriene C4 (LTC4) by
preparations of renal cortex. There was a significant inverse correlation
between GFR and in vitro production of both LTC4 and LTB4 in
kidneys from MRL-lprllpr mice, but not in control animals. In addition,
in vitro LTC4 production was correlated with the severity of renal
histomorphologic abnormalities. Administration of the specific peptido-
leukotriene receptor antagonist SKF 104353 to 20 week old MRL-lprllpr
mice significantly improved both GFR and CPAH, whereas this agent
had no effect of renal hemodynamics in MRL-+/+ controls. These
results suggest that renal production of LTC4 and LTB4 is increased in
MRL-lprllpr mice with nephritis, and that enhanced production of
peptidoleukotrienes causes reversible renal dysfunction. Increased
leukotriene production within the kidney may therefore be important in
the pathogenesis of lupus nephritis.
Glomerulonephritis with progressive renal failure continues
to be an important cause of morbidity and mortality in patients
with SLE [1—31. Although the mechanisms promoting abnormal
immune function and autoantibody production in SLE have
received much attention 12—51, the specific effector systems
which produce renal injury in lupus have not been as well
characterized. Previous studies have suggested that alterations
in arachidonic acid metabolism may be important in the patho-
genesis of lupus nephritis 16—91. Enhanced production of cyclo-
oxygenase metabolites has been documented in murine lupus
[6, 7] as well as in humans with SLE [8, 9]. However, little is
known about the potential role of altered lipoxygenase metab-
olism in renal disease associated with lupus.
Leukotrienes are 5-lipoxygenase products of arachidonic acid
that have a number of biologic actions which may be specifi-
cally relevant to the pathogenesis of renal disease [10]. For
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example, the peptidoleukotrienes (LTC4 and LTD4) cause renal
vasoconstriction [11—14], induce mesangial cell contraction and
proliferation [15, 16], stimulate production of extra-cellular
matrix proteins [17] and may increase production of other
inflammatory lipid mediators [18, 19]. In addition, LTB4 stim-
ulates chemotaxis 120], promotes adhesion of leukocytes to
endothelial cells [21] and may modulate production of interleu-
kin 1 [22], which has been implicated as a mediator of renal
damage in lupus [23]. Thus, increased production of these lipid
mediators within the kidney during disease states could pro-
mote glomerular inflammation and injury.
To investigate the functional role of leukotrienes in lupus, we
utilized the MRL/MpJ-lpr/lpr strain of autoimmune mice (MRL-
lpr/lpr). These animals spontaneously develop an autoimmune
disease with nephritis similar to human SLE [5]. In this model,
disease expression is regulated by a single autosomal recessive
gene (lpr), although background genes contribute to the severity
and pattern of disease manifestations. As controls, we used
MRL-+/+ mice which are a congenic strain that lack the lpr
gene and develop a late onset, mild form of autoimmunity.
Because accurate measurement of renal function in mice is
technically difficult, previous studies in murine models of lupus
have relied almost exclusively on renal histomorphology, pro-
teinuria and animal death as outcome measures. However, by
applying procedures adapted from hemodynamic studies in the
rat [24], we have been able to make reliable and reproducible
measurements of renal function in mice. These studies were
facilitated by the large body size of MRL mice and thus allowed
evaluation of the renal hemodynamic consequences of altered
arachidonic acid metabolism in this model.
In the present study, we found that MRL-lpr/lpr mice develop
significant renal dysfunction by 20 weeks of age. In these
animals, impaired renal function was associated with increased
in vitro production of both leukotrienes C4 and B4. Enhanced
leukotriene production by the kidney correlated with the level
of renal hemodynamic impairment and the severity of renal
histomorphologic abnormalities. Administration of the specific
peptidoleukotriene receptor antagonist SKF 104353 produced a
significant improvement in renal function in MRL-lprllpr mice
but had no effect in MRL-+/+ controls. Our studies suggest
that increased production of lipoxygenase metabolites within
the kidney may be important in the pathogenesis of murine
lupus nephritis.
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Methods
Animals
MRL-lprllpr and MRL-+/+ mice were originally obtained
from the Jackson Laboratory (Bar Harbor, Maine, USA).
These animals were maintained and subsequently bred in the
animal facility of the Durham VA Medical Center. Normal
outbred laboratory mice (Charles Rivers Laboratories, Wilming-
ton, Massachusetts, USA) were used as additional controls. All
animals were given standard laboratory chow and tap water ad
libitum.
Measurement of renal function in MRL mice
Inulin and PAH clearances were measured in mice using a
procedure for surgical preparation which was adapted from that
used in rats. MRL-lpr/lpr (N = 22) and MRL-+/+ (N = 18)
animals were studied at 12 and 20 weeks of age. On the day of
the study, mice were anesthetized with 0.04 mglg body weight
pentobarbital, and a polyethylene catheter (PE90) inserted into
the trachea to facilitate spontaneous ventilation. The left ca-
rotid artery and left jugular vein were cannulated with polyeth-
ylene catheters (PE1O) for intravenous infusions, to monitor
mean arterial pressure (MAP), and to allow intermittent sam-
pling of arterial blood. After volume replacement with normal
saline (2% of body wt over 20 mm), priming doses of 14C-inulin
and 3H-PAH were given followed by a continuous infusion of
inuljn and PAH to maintain constant blood levels. The bladder
was cannulated via a suprapubic incision with a polyethylene
catheter (PESO). After a 30-minute equilibration period, clear-
ances of inulin (C1) and PAH (CPAH) were measured during
three 30-minute urine collections. Arterial blood samples were
obtained at the mid-point of each collection. Tritium and 14C
radioactivity were measured in plasma and urine with a dual
channel liquid scintillation system (Nuclear Chicago-TM Ana-
lytic Inc., Elk Grove Village, Illinois, USA), and clearances
were calculated using standard formulas.
For the inhibitor studies, MRL-lpr/lpr and MRL-+/+ animals
were studied at 20 weeks of age. The preparation procedure was
identical to that outlined above. After two 20-minute baseline
clearance periods, an intravenous bolus of 1 mg/kg of the
specific peptidoleukotriene receptor antagonist SKF 104353
(2(S)-hydroxy-3(R)- [(2-carboxyethyl)thiol -3- [2-(8-phenyloctyl)
phenyll-propanoic acid; Smith Kline, and French Laboratories,
King of Prussia, Pennsylvania, USA) [25—27] was given fol-
lowed by a continuous infusion of 3 mg/kg/hr into the jugular
vein. This dose range blocks the renal hemodynamic effects of
intravenous infusions of LTD4 in rats [14]. Following 20 min-
utes of equilibration, renal function was measured during two
additional 20 minute periods to assess the effects of leukotriene
receptor blockade.
Leukotriene production by renal cortical homogenates
Following the renal hemodynamic studies, MRL-lpr/lpr,
MRL-+/+ and normal mice were sacrificed and kidneys pre-
pared for measurements of renal leukotriene production and
histopathologic examination. For the leukotriene measure-
ments, the left kidney was rapidly removed, weighed, and
placed in Kreb's buffer at 4°C. The kidney was bisected and a
central slice obtained. Cortex was separated from medulla by
macrodissection. Portions of cortex were uniformly minced
with a razor blade and suspended in 2 ml of iced Kreb's buffer
containing 5ILM A23187. The suspensions were incubated for
thirty minutes at 37°C in 95% 02. Samples were centrifuged at
2000 rpm for 10 minutes at 4°C and supernatants were stored at
—70°C until leukotrienes were measured as described below.
The tissue pellet was resuspended in 0.5 ml of cold Kreb's
buffer and the protein concentration was measured using the
Coomassie Brilliant Blue dye-binding assay (Bio-Rad) [28].
Quantitation of leukotrienes
Radioimmunoassays (RIA). Concentrations of LTB4 and
LTC4 in unextracted supernatants from incubations of renal
cortex were measured by RIA (Amersham, Arlington Hts,
Illinois, USA). For the LTB4 assay, samples (measured in
duplicate) and standards (measured in triplicate) were incu-
bated with known quantities of [3H]-LTB4 and antisera at 25°C
for two hours. For the LTC4 assay, the procedure was similar
except that incubation was for 16 hours at 4°C. The concentra-
tion of unlabeled LTB4 that inhibited 50% binding of II3HILTB4
tracer was 41.7 7.1 pg/l00 tl (mean standard error of 4
assays) and the lower limit of detectability was 0.5 pg/tOO 1.d.
The concentration of unlabeled LTC4 that inhibited 50% bind-
ing of [3H]LTC4 tracer was 48.5 0.6 pg/100.d (mean
standard error of 4 assays) and the lower limit of detectability
was 3 pg/l00 pi. After incubation, unbound eicosanoids were
removed from the mixture with a suspension of dextran-coated
activated charcoal. Sample concentrations were determined by
a standard curve in which the logarithm of the concentration is
plotted versus the logit of the B/Bo value. Results were ex-
pressed as picograms/minute/milligram protein. We found that
the cross reactivity of the LTB4 antibody was < 1% with LTC4,
LTD4, and LTE4 and cross reactivity of the LTC4 antibody was
<5% for LTD4 and <1% for LTE4 and LTB4.
High-performance liquid chromatography (HPLC). To con-
firm the specifity of the leukotriene assays, selected superna-
tants from incubations of renal cortex with ionophore were
pooled and separated by HPLC prior to measurement of LTC4
and LTB4 by RIA. These samples were acidified and applied to
C-l8 columns preconditioned with methanol and water. After
washing, the samples were eluted with a 70% solution of
acetonitrile in water. Samples were evaporated to dryness
under nitrogen and then reconstituted in a 1:1 solution of
acetonitrile and 2.5 mivi trifluoroacetic acid. To separate leuko-
trienes, a Pecosphere HS3-C18 cartridge (Perkin-Elmer Corp.,
Norwalk, Connecticut, USA) was used.
Samples and leukotriene standards (Advanced Magnetics
Inc., Cambridge, Massachusetts, USA) were injected onto the
column and eluted with a linear a gradient from 100% 2.5 mM
trifluoroacetic acid to 100% acetonitrile over eight minutes at a
flow rate of 3.0 ml/min. Elution of leukotrienes from the column
was monitored by absorbance at wavelength 280 nm with a
programmable multiwavelength UV spectrophotometer (Wa-
ters Associates, Milford, Massachusetts, USA). All separations
were performed at ambient temperature. Collected fractions
were evaporated to dryness under nitrogen and reconstituted in
appropriate buffer for quantitation of leukotrienes by RIA.
Using this technique, recoveries ranged from 70 to 75% for
LTB4 and 40 to 60% for LTC4.
To investigate the specificity of the radioimmunoassays for
LTC4 and LTB4, pooled supernatants from cortical incubations
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Fig. 1. HPLC separation of leukotrienes. Supernatants from renal
cortical incubations were separated by HPLC and column eluate
fractions collected based on the retention time of leukotriene standards
(A). Concentrations of LTB4 (B) and LTC4 (C) in specific eluate
fractions were measured by radioimmunoassay. The peak of immuno-
reactive LTB4 and LTC4 eluted at the same time as their corresponding
authentic leukotriene standards.
were separated by HPLC and concentrations of LTC4 and
LTB4 in specific eluate fractions were determined by RIA as
described above. The results of these studies are shown in
Figure 1. Column eluate fractions were collected based on the
appearance of absorbance peaks at 280 nm for leukotriene
standards (Fig. 1A). The peak of immunoreactive LTB4 eluted
at the same time as leukotriene B4 standard (Fig. lB). Similarly,
the peak of immunoreactive LTC4 eluted with the absorbance
peak of leukotriene C4 standard (Fig. IC).
Histologic studies
Formalin fixed tissue stained with hematoxylin and eosin or
Masson trichrome was examined by light microscopy. The
slides were reviewed by a pathologist (PR) blinded to the age
and strain of the mice. As reported previously [29], tubuloin-
terstitial, vascular, and glomerular abnormalities were graded
using a semiquantitative scale where 0 was no abnormality, and
1+, 2+, 3+, and 4+ represented mild, moderate, moderately-
severe, and severe abnormalities, respectively. An overall
histologic score was obtained by summing these values.
Statistical analysis
Data are presented as the mean standard error of the mean.
For the hemodynamic studies, data points for each animal
represent the mean of the values measured during at least two
clearance periods. For comparisons between two groups, sta-
tistical significance was assessed using an unpaired t-test. For
comparisons within the same group a paired t-test was used.
For comparisons between more than two groups, statistical
analysis was performed by one-way analysis of variance fol-
lowed by Bonferroni's procedure for multiple pairwise compar-
isons [30]. Correlations were assessed by linear regression
analysis.
Results
Although specific measurements of renal function in MRL
mice have not been previously reported, we measured GFR and
PAH clearance at time points which have been characterized
histolopathologically as corresponding to early and late phases
of disease [5]. As depicted in Figure 2, between 12 and 20 weeks
of age MRL-lpr/lpr animals develop functional manifestations
of nephritis. Inulin clearance is significantly reduced in MRL-
lpr/lpr mice at 20 weeks (6.3 0.8 ml/min/kg) compared to the
normal levels seen at 12 weeks of age (9.7 0.4 mllmin/kg; P <
0.01). Similarly, PAH clearance was significantly lower in 20
week old (24.3 3.3 mllmin/kg) compared to 12 week old
MRL-lprllpr animals (35.2 0.7 mI/mm/kg; P < 0.01). Although
renal function deteriorated with age in MRL-lpr/lpr mice, there
was no change in renal function in MRL-+/+ controls over this
same time period. Thus, by 20 weeks of age both GFR and PAH
clearance were significantly reduced in MRL-lpr/lpr mice com-
pared to MRL-+/+ controls (GFR: 10.0 0.5 mllmin/kg and
CPAH: 43.6 4.1 ml/minlkg; P < 0.01 vs. 20 week MRL-lpr/
lpr).
Along with this deterioration in renal function, the severity of
renal histomorphologic abnormalities was also dramatically
increased between 12 and 20 weeks in MRL-lprllpr mice. By
light microscopy, kidneys from 12 week old MRL-lpr/lpr mice
appeared normal. A representative photomicrograph of a kid-
ney section from a 12 week old MRL-lpr/lpr animal is shown in
Figure 3A which demonstrates normal glomerular and intersti-
tial architecture. By 20 weeks, these animals typically mani-
fested a proliferative glomerulonephritis with scattered crescent
formation, perivascular and interstitial inflammation and focal
areas of interstitial fibrosis and glomerulosclerosis. Repre-
sentative severely affected glomeruli in a 20 week old MRL-lpr/
lpr mouse are shown in Figure 3B. The interstitial inflammation
typically seen in MRL-lpr/lpr animals at this age can also be
easily appreciated. Significant morphologic abnormalities were
not observed out to 20 weeks in the MRL-+/+ group. Thus, the
semi-quantitative histopathologic score in 20 week old MRL-
lprllpr mice (5.3 1.0) was higher than that of either 12 week
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Fig. 2. Renal hemodynamic function in MRL mice. Inulin clearance(A) and PAH clearance (B) were measured in MRL mice at 12 weeks of
age (open bars) and 20 weeks of age (hatched bars). Clearances of inulin
and PAH were significantly reduced in 20 week old MRL-lpr/lpr mice
compared to either 12 week old MRL-lprllpr or 20 week old MRL-+/+
mice. (*P < 0.01 vs. 12 week old MRL-lpr/lpr mice; tP < 0.01 vs. 20
week old MRL-+/+ controls.)
old MRL-lpr/lpr (2.5 0.3) or 20 week old MRL-+/+ animals
(2.0 0.6; P < 0.01).
The functional and histomorphologic abnormalities observed
in 20 week old MRL-lpr/Ipr mice were associated with an
enhancement of in vitro production of 5-lipoxygenase metabo-
lites by the kidney. As shown in the Figure 4, ionophore-
stimulatéd production of LTC4 by homogenates of renal cortex
from MRL-/pr//pr mice was significantly increased at 20 weeks
(120 12 pglmin/mg protein; P < 0.005) compared to 12 weeks
(71 10 pg/mm/mg ptotein). Similarly, there was a significant
increase in LTB4 production by kidneys from MRL-lprllpr
animals between 12 weeks (3.9 0.5 pg/mm/mg protein) and 20
weeks of age (8.2 2.1 pg/mm/mg protein; P <0.01). In
contrast, there were no significant differences in renal produc-
tion of LTC4 and LTB4 in MRL-+/+ animals at 12 weeks
(LTC4: 85 10; LTB4: 3.0 pg/mm/mg protein) compared
to 20 weeks of age (LTC4: 102 10; LTB4: 4.9 0.8 pg/mm/mg
protein). However, ionophore-stimulated LTC4 production by
kidneys from MRL-lpr/lpr and MRL-+/+ animals in both age
groups was significantly higher than that of normal mice (34
4 pg/mm/mg protein; P < 0.005 vs. all MRL groups).
Figure 5 shows the relationship between in vitro production
of LTC4 and GFR in MRL-lpr/lpr mice. There was a significant
inverse correlation between in vitro production of LTC4 and
GFR in MRL-lpr/lpr mice (r = 0.77, P < 0.0001). A similar
inverse correlation between renal production of LTB4 and GFR
(P = 0.66, P < 0.005) was also present. Furthermore, we found
a positive association between LTC4 production and the overall
renal histopathologic score (r =0.70, P <0.005). There were no
significant correlations between production of either LTC4 or
LTB4 and renal function in MRL-+/+ animals.
To investigate the functional significance of increased renal
leukotriene production in MRL-lpr/lpr mice, we evaluated the
renal hemodynamic effect of the specific peptidoleukotriene
receptor antagonist SKF 104353 in MRL mice at 20 weeks of
age. The effects of SKF 104353 on renal function in 20 week old
MRL mice are shown in Table 1. After a 1 mg/kg intravenous
bolus followed by continuous infusion of SKF104353 at 3
mg/kg/hr, both inulin and PAR clearances increased signifi-
cantly in the MRL-lpr/lpr animals. In contrast, SKF104353 had
no effect on renal function in MRL-+/+ controls. In addition,
the peptidoleukotriene receptor antagonist did not affect mean
arterial pressure in either group.
Discussion
Eicosanoids generated as part of the inflammatory response
may be important in the pathogenesis of several immune-
mediated kidney diseases including murine lupus [31]. In au-
toimmune mice, enhanced production of cyclo-oxygenase
metabolites by the kidney has been clearly documented [6, 7].
Although a role for 5-lipoxygenase products in lupus nephritis
has not been previously demonstrated, leukotrienes have a
number of biologic properties that may be relevant to the
pathogenesis of renal disease [10—22]. In the present study, we
found that GFR and CPAH were reduced by more than 30% in
MRL-lpr//pr mice at 20 weeks of age. In these animals with
renal dysfunction, in vitro production of leukotrienes C4 and B4
by the kidney was increased significantly compared to 12 week
old MRL-lpr//pr mice with normal renal function. This age
related increase in leukotriene production was not observed in
MRL-+/+ controls.
In the present study, administration of the specific peptido-
leukotriene receptor antagonist SKF 104353 significantly in-
creased both GFR and CPAH in 20 week old MRL-lpr//pr mice
but had no effect on renal function in MRL-+/+ controls.
SKF104353 is a highly potent and selective peptidoleukotriene
receptor antagonist [25—27]. This compound has been shown to
specifically reverse the physiologic effects of LTC4 and LTD4 in
renal vasculature [141 and lung tissue [25, 26]. Furthermore,
recent studies by Badr et al have shown that this compound
inhibits specific binding of LTD4 to mesangial cells in a highly
potent and specific manner [161. Thus, in our study, the
combined demonstration of increased LTC4 production in vitro
by MRL-lpr/lpr kidneys and the significant improvement in
renal function when SKF 104353 is infused in vivo suggests that
peptidoleukotrienes may mediate renal hemodynamic impair-
ment in this murine model of SLE.
Peptidoleukotrienes may impair renal function by several
mechanisms. Both LTC4 and LTD4 produce intense renal
vasoconstriction and decrease renal blood flow [11—14]. In
addition, peptidoleukotrienes stimulate mesangial cell contrac-
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Fig. 3. Photomicrographs of kidney sections from MRL-lpr/lpr mice. A. Normal glomerular and interstitial architecture are demonstrated in this
representative section from a 12 week old MRL-lpr/lpr mouse. B. Proliferative glomerulonephntis with crescent formation and interstitial
inflammation are seen in this severely affected kidney from a 20 week old MRL-lpr/lpr animal. The sections are stained with hematoxylin and eosin
and the magnification is 250x.
tion [15, 16] causing a reduction in the glomerular ultrafiltration
coefficient (K1) [13]. In this regard, in a rat model of nephrotoxic
serum nephritis [32], Badr et al found that administration of a
specific peptidoleukotriene receptor antagonist improved GFR
by preventing the reduction in Kf associated with administra-
tion of nephrotoxic serum. In the present study, we found that
treatment with SKF 104353 increased GFR by approximately
40% and CPAH by approximately 30% in animals with nephritis.
This suggests that the improvement in GFR cannot be attrib-
uted solely to changes in renal blood flow and that some of the
beneficial effects of peptidoleukotriene receptor blockade in
this model may be related to changes in the glomerular ultrafil-
tration coefficient. Furthermore, the improvement in renal
hemodynamics we observed in 20 week old MR1-lpr/lpr mice
occurred despite severe alterations in renal histology in these
animals. Thus, even in advanced stages of the nephritis, a
significant component of renal dysfunction is hemodynamically
mediated, and reversible.
In addition to the effects of sulfidopeptide leukotrienes on
renal hemodynamics in this model, our data suggest that
stimulated production of LTB4 may also play a role in lupus
nephritis. In the MRL-lpr/lpr group, we found a significant
inverse correlation between LTB4 generation and GFR. Al-
though LTB4 is not vasoactive, it has a number of biologic
effects which could contribute to the development of renal
inflammation and injury. For example, LTB4 is a potent chemo-
tactic agent [20] and enhances aggregation, enzyme release, and
generation of reactive oxygen species by neutrophils [20, 33].
Recruitment and activation of neutrophils are important in the
pathogenesis of renal injury in both human and animal models
of immune-mediated kidney diseases [341.
Another property of leukotrienes that may be important in
renal disease is their ability to stimulate production of other
inflammatory mediators [18, 19, 22]. For example, the peptido-
leukotrienes, LTC4 and LTD4, stimulate synthesis of throm-
boxane A2 by macrophages [18] and guinea pig lung [19]. Since
renal thromboxane production is increased in MRL-lpr/lpr mice
[7], it is possible that some portion of the beneficial effect of
leukotriene receptor antagonism which we observed in the
animals with nephritis might be related to inhibition of leuko-
triene stimulated thromboxane production. However, in the
isolated perfused rat kidney, the renal vasoconstrictive effects
of LTC4 and LTD4 are not blocked by inhibition of cyclooxy-
genase orthromboxane synthase [11,351. Furthermore, in other
studies, we have found that complete renal thromboxane recep-
tor blockade in 20 week old MRL-lprllpr animals produced only
minimal improvement in renal function [36].
There are several potential cellular sources of leukotriene
production in lupus nephritis. Glomeruli, renal tubules, resident
macrophages within glomeruli and various infiltrating inflam-
matory cells are capable of synthesizing lipoxygenase products
[10, 37, 38]. Macrophages are a prominent component of the
cellular infiltrates in the kidneys of MRL-lpr/lpr mice with
nephritis [39] and may represent a primary source of leuko-
triene production in this model. In this regard, Santoro et al [40]
found that peritoneal macrophages from MRL-lpr/lpr mice
exhibited enhanced production of LTC4 in response to zymosan
stimulation. Furthermore, macrophages from MRL-+/+ ani-
mals showed a similar abnormality when compared to macro-
phages derived from other non-MRL strains.
In all of the MRL groups, we found renal LTC4 production to
be significantly increased compared to normal, non-MRL con-
trols. Within the MRL-lpr//pr group, renal LTC4 production
correlated inversely with renal function measured in vivo and
positively with histopathologic score. In addition, the receptor
antagonist significantly improved renal function only in 20 week
old MRI-lpr/lpr group. This suggests that, at least in the
MRL-lprllpr animals, in vitro measurement of renal LTC4
production reflects a stimulation of LTC4 production in vivo.
The physiologic significance of the elevation of LTC4 produc-
tion in the MRL-+/+ group is more problematic. Because the in
vitro assay is performed after the addition of calcium iono-
phore, this is a stimulated measurement which probably reflects
a maximal capacity for renal leukotriene synthesis. The recep-
100 Spurney et al: Renal leukotriene production in murine lupus
MRL-Ipr MRL-+ +
Fig. 4. Renal leukotriene production in MRL mice. Production of
LTB4 (A) and LTC4 (B) was measured in homogenates of renal cortex
incubated with 5 /.LM A23 187. Production rates were measured in MRL
mice at 12 weeks of age (open bars) and 20 weeks of age (hatched bars).
In kidneys from MRL-/pr//pr mice, A23l87 stimulated production of
LTB4 and LTC4 increased significantly between 12 and 20 weeks of age.
(* < 0.01 vs. 12 week old MRL-lprllpr mice.)
LTC4, pg/rn/n/mg protein
Fig. 5. Relationship between renal leukotriene production and inulin
clearance. In MRL-lprllpr mice, there was a significant inverse cone-
lation between GFR and in vitro renal production of both LTB4, shown
in panel A (r = 0.66, P < 0.005), and LTC4, shown in panel B (r = 0.77;
P < 0.0001).
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Table 1. Hemodynamic effect of SKF104353 in MRL micetor antagonist data suggest that within the ++ group this
abnormal stimulation of LTC4 production in vitro is not mir-
rored by an increase in production in vivo. In this model, the
MRL genetic background appears to contribute to the severity
and anatomic distribution of disease expression. For example,
non-MRL background strains which bear the lpr gene produce
several types of autoantibodies, but do not develop the nephri-
tis or arthritis typically seen in MRL-/pr//pr mice [41—43]. Thus,
the enhanced capacity for renal LTC4 production which we
observed in MRL-+/+ animals may be a predisposing factor for
the development of functional renal disease when the immuno-
logic abnormalities associated with the lpr gene are superim-
posed.
Several groups have previously demonstrated that dietary
interventions which affect lipid metabolism such as fish oil
feeding [6, 44] or essential fatty acid deficiency [45] can
ameliorate nephritis in mice prone to develop autoimmune
disease. Kelley and associates have postulated that the benefi-
cial effects of fish oil feeding may be related in part to reduced
5.9 1.8
20.4 4.7
114 9
10.3 0.6
49.2 7.0
114 5
8.1 2.3a
26.8 .oaIll 9
10.4 1.3
44.3 3.6
119 6
production of cyclo-oxygenase products in animals fed fish oil
[6]. Other investigators have suggested that the beneficial
effects of essential fatty acid deficiency may be related to
inhibition of lymphocyte or macrophage function [451. Both of
these dietary interventions can have profound effects of lipoxy-
genase metabolism [37, 46, 47]. For example, essential fatty
Spurney et al: Renal leukotriene production in murine lupus 101
acid deficiency reduces glomerular LTB4 production [37]. In
addition, eicosapentaenoic acid, which is a major constituent of
fish oil, inhibits generation of 5-lipoxygenase products by
leukocytes [46]. LTB5, which is produced through 5-lipoxygen-
ation of eicosapentaenoic acid, is markedly less potent than
native LTB4 [47]. Our data suggest that some of the beneficial
effects of these dietary interventions could relate to reduced
formation of functional lipoxygenase products.
A role for increased renal lipoxygenase activity has been
suggested in other experimental models of glomerulonephritis
[32, 48, 49]. In a rat model of membranous nephropathy,
Rahman et al [48] found an increase in LTB4 production by
isolated glomeruli which does not depend on infiltration by
inflammatory cells. In nephrotoxic serum nephritis in the rat,
renal synthesis of hydroxyeicosatetraenoic acids and leuko-
triene B4 are increased in the early heterologous phase of the
disease [49]. In this model, peptidoleukotriene receptor block-
progressive renal damage in lupus.
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